Treatment/medications
Therapeutic algorithms for children with rhinitis in children are long
based on the same principles as in adults [85]. During the past two
decades ARIA has proposed an evolving guideline for the management of
patients with AR. More recently, intergraded care pathways (ICPs) have
been proposed, based on technology-evident information, providing a
self-care plan by a multidisciplinary group of health professionals
centered around the patient [59]. In specific, an algorithm based on
the visual analogue scale (VAS) for assessing rhinitis symptoms has been
revised by the ARIA expert group for (1) selection of pharmacotherapy
for patients with AR and (2) to tailor treatment depending on control
[86].
ARIA has been the first guideline in the field of allergy to have used
the GRADE system to formally evaluate and appraise evidence. In its
latest update, an important step is the addition or real-life evidence,
supported through an mHealth application [59]. Real-life approaches
are increasingly used to complement randomized trials, in order to
expand the scope and evaluate external validity of the findings
[87].
Treatment of AR includes allergen avoidance whenever possible, use of
medications and allergen specific immunotherapy (AIT)